Opthea controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C, VEGF-D and VEGF receptor-3 (VEGFR-3).
Our lead molecule is a soluble form of VEGFR-3, OPT-302 (formerly VGX-300), that acts as a VEGF-C/VEGF-D ‘trap’. The molecule blocks blood and lymphatic vessel growth and inhibits vascular leakage. OPT-302 is initially being developed for the treatment of neovascular (‘wet’) age-related macular degeneration (wet AMD), the leading cause of blindness in the Western world, with the potential to expand our development program for other eye diseases.
OPT-302 may be used as a stand-alone (so-called "single-agent" or "mono") therapy or in combination with existing VEGF-A inhibitors in patients with wet AMD.
Our strategy is to achieve a more complete blockade of the VEGF family of proteins and more effectively block the abnormal blood vessel growth and vessel leakage that occurs at the back of the eye in people with wet AMD. By inhibiting these processes, our objective is to improve patients' vision.